ClinicalTrials.gg
RecruitingNCT07382986IMPACTUpdated Sep 21, 2026

IMPACT COPD Cohort (China)

An observational study in Chronic Obstructive Pulmonary Disease (COPD) and Multimorbidities, sponsored by Beijing Chao Yang Hospital. Recruiting at 4 sites in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Beijing Chao Yang Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital — 6 open to participants now, 6 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Beijing Chao Yang Hospital.

Started
2026
with 2 others
Observational
7 of 13
5 open now
Registered
11th of 13
by date

Among the 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital, this one is one of 3 that started in 2026, is one of 7 observational ones, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is a major chronic respiratory condition with high prevalence of multimorbidity. COPD and comorbidities interact dynamically, contributing to symptom fluctuation, acute exacerbations, hospitalization, and long-term disease progression.

The IMPACT COPD Cohort (China) is a multicenter prospective observational cohort designed to establish a real-world evidence base for integrative Chinese-Western medicine management of COPD with comorbidities. The cohort integrates conventional clinical assessments (symptoms, questionnaires, spirometry, imaging, and biomarkers) with continuous multisensor digital monitoring (e.g., heart rate, blood pressure, activity, sleep patterns, and other physiological and behavioral measures) and digital Traditional Chinese Medicine (TCM) phenotyping (e.g., tongue, pulse, and facial diagnostics).

The study aims to characterize risk profiles of high-risk populations and patients with confirmed comorbidities, develop and validate prediction models for comorbidity risk and acute exacerbation events, and support evidence generation for long-term management strategies with early screening and risk warning capabilities across hospital, community, and home settings.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Multimorbidities
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from multiple hospitals in China. Eligible participants are adults aged 40-85 years with COPD diagnosed according to the 2025 GOLD criteria, identified in outpatient clinics and/or inpatient settings and enrolled for prospective follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-85 years;
  • Diagnosis of (COPD) according to the 2025 GOLD criteria.

Exclusion criteria

Exclusion Criteria:

  • Acute exacerbation of within the past 4 weeks;
  • Presence of other pulmonary diseases causing chronic respiratory failure in addition to COPD, such as severe bronchiectasis, pneumoconiosis, post-tuberculosis destroyed lung, chest wall deformity, or neuromuscular disease;
  • Cystic fibrosis or interstitial lung disease;
  • Severe respiratory failure requiring long-term mechanical ventilation via tracheostomy;
  • History of lung or other organ transplantation;
  • Severe pleural disease or chest wall abnormalities that interfere with imaging or pulmonary function assessment;
  • Lung cancer or other with widespread disease;
  • Previous or current chemotherapy and/or radiotherapy that may affect pulmonary function or structural assessment;
  • Uncontrolled rheumatic/ diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus);
  • infection;
  • Long-term use of agents or systemic ;
  • Severe organ dysfunction, such as severe cardiac, hepatic, or renal failure, or severe pulmonary arterial hypertension;
  • Hospitalization due to myocardial infarction, heart failure, or other cardiovascular events within the past 3 months;
  • Major surgery involving the chest, abdomen, or eyes within the past 3 months;
  • Presence of intrathoracic metallic foreign bodies or implants that interfere with imaging assessment (e.g., pacemaker, implantable cardioverter-defibrillator, metallic prosthetic valves, other metallic devices, or shrapnel);
  • Allergy to any component of the Chinese herbal compound formula(s);
  • Allergy to any component of ICS+LABA+LAMA therapy or to inhaler propellants/;
  • Pregnant or breastfeeding women;
  • Long-term bedridden status, loss of ability to perform activities of daily living, or \<1 year;
  • Dementia or other cognitive impairment preventing and follow-up;
  • Living far from the study center, or planned relocation within the next 3 years, making follow-up infeasible;
  • Current participation in another interventional clinical trial involving the respiratory system;
  • Refusal to provide written informed consent.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Interventions

  • OtherNot applicable- observational study

    For this observational study, participants are not assigned an intervention as part of the study.

06

What researchers measure

Primary outcomes

  1. Annual rate of COPD exacerbation

    Time frame: up to 36 months

  2. Incidence of COPD-related comorbidities (hypertension, coronary artery disease, arrhythmia, heart failure, diabetes, etc.)

    Time frame: up to 36 months

07

Study locations

4 of 4 sites recruiting
  • Hebi Coal Industry Group General Hospital
    Hebi, Henan, China
    Recruiting
  • Tongliao Second People's Hospital
    Tongliao, Neimeng, China
    Recruiting
  • Mianyang Third People's Hospital
    Mianyang, Sichuan, China
    Recruiting
  • The First Affiliated Hospital of Shihezi University
    Shihezi, Xinjiang, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2030, 47 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 47 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Feb 25, 2030
CompletionEst.
Feb 25, 2030
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07382986
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Feb 26, 2026
Primary completion
Feb 25, 2030 (estimated)
Completion
Feb 25, 2030 (estimated)
Last update
Sep 21, 2026

Study contacts

Zujin Luo, MD
Contact
xmjg2002@163.com
+86-13810497587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion